271 results on '"Tormene D"'
Search Results
52. Evidence of the first X-linked thrombophilia due to a novel mutation in clotting factor IX gene resulting in hyperfunctional fix: factor IX arginine 338 leucine (factor IX padua)
53. Thrombosis in children
54. Increased endogenous thrombin potential (ETP) in carriers of inherited clotting inhibitors defects
55. Increased Endogenous Thrombin Potential (ETP) in patients of families with inherited AT defects
56. Thrombophilia as a predictor of residual vein thrombosis. A prospective cohort study
57. Screening for venous thrombophilia: pros
58. Thrombophilia and thrombosis in adults and children
59. Sudden hearing loss followed by deep vein thrombosis and pulmonary embolism in a patient with factor V Leiden mutation
60. The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia
61. Venous thromboembolism, fetal loss and preeclampsia in pregnant women with congenital thrombophilia
62. 4G/5G polymorphism of PAI-1 gene promoter: an additional possible prothrombotic factor in congenital thrombophilia
63. Combination of 4 mutations (FV R506Q, FV H1299R,Fv Y1702C, PT 20210)affecting the prothrombinase complex in a thrombophilic family
64. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study
65. 0.10b Low-molecular-weight heparin for prevention of obstetric complications in carriers of factor V Leiden or PT-G20210A mutation
66. P.28 Factor V Leiden, PT-G20210A, MTHFR C677T mutations and the risk of implantation failure in women undergoing assisted reproductive procedures (IVF or ICSI)
67. Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency
68. Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from mixed type I/III families
69. O5 Microparticles plasma levels in women with venous thromboembolism and cancer
70. Thrombophilia as a predictor of persistent residual vein thrombosis
71. MORE SEVERE HYPERCOAGULABLE STATE IN PROTHROMBIN G20210A CARRIERS THAN IN NON-CARRIERS WITH COMPARABLE PROTHROMBIN LEVELS
72. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients
73. Th-P15:45 Increased levels of small, dense, oxidized LDL in patients with idiopathic venous thromboembolism: A common link with atherosclerosis
74. Mo-P1:127 Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis
75. Below-knee elastic compression stockings for prevention of the post-thrombotic syndrome in patients with proximal-vein thrombosis: a prospective controlled randomized study
76. Long-Term Use of Oral Contraceptive Therapy in Women With the Prothrombin 20210 G-A Polymorphism Without Thrombotic Complications: A Study of 13 Women (12 Heterozygotes and 1 Homozygote)
77. Heterozygous carrier of G20210A prothrombin mutation used oral contraceptive treatment for 23 years without thrombotic events, and developed cerebral venous thrombosis 1 month after resumption of the medication at the age of 50
78. Clinical and laboratory expression of associated thrombophilic conditions (homozygous/heterozygous factor V Leiden mutation and heterozygous prothrombin variant 20210A) in an Italian family
79. It is not sure yet whether the nt 20210 G to A prothrombin polymorphism represents a cause of familial venous thrombophilia
80. Factor V variants, activated protein C resistance and venous thromboembolism
81. Pitfalls of protein C assays in patients with activated protein C resistance
82. Prolonged oral contraceptive therapy in a woman with an antithrombin III abnormality involving heparin binding (Type lie) without thromboembolic complications
83. X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua)
84. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial.
85. Megakaryocytes endocytose and subsequently modify human factor V in vivoto form the entire pool of a unique platelet-derived cofactor
86. APC resistance, oral contraceptive therapy and deep vein thrombosis: Settled and unsettled problems
87. Hyperhomosysteinemia and deep-vein thrombosis. A case-control study
88. Factor V Leiden mutation and the risk of venous thromboembolism in pregnant women
89. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S
90. Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred
91. Factor V Leiden and prothrombin gene mutation in inflammatory bowel disease in a Mediterranean area
92. Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)
93. Venous Thromboembolism in Children: The Rivaroxaban Experience.
94. Corrigendum: The new Italian registry of infantile thrombosis (RITI): a reflection on its journey, challenges and pitfalls.
95. POST-discharge thromboprophylaxis in patients with COVID-19: a single-center experience.
96. Age over 75 does not increase the risk of recurrent venous thromboembolism: Findings from the RIETE registry.
97. Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death.
98. Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study.
99. Treatment of Refractory/High-Risk Pregnancies With Antiphospholipid Syndrome: A Systematic Review of the Literature.
100. Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.